- Home
- CMDB vs ZVRA Comparison
CMDB vs ZVRA Comparison
Compare CMDB & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMDB | ZVRA |
|---|---|---|
| Founded | 2023 | 2006 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.1M | 472.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | CMDB | ZVRA |
|---|---|---|
| Price | $17.30 | $8.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.71 |
| AVG Volume (30 Days) | 58.9K | ★ 553.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.27 |
| EPS | N/A | ★ 1.16 |
| Revenue | N/A | ★ $23,612,000.00 |
| Revenue This Year | N/A | $333.64 |
| Revenue Next Year | N/A | $44.19 |
| P/E Ratio | ★ N/A | $7.73 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.46 | $6.19 |
| 52 Week High | $19.93 | $13.16 |
Technical Indicators
Market Signals| Indicator | CMDB | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 55.64 |
| Support Level | $14.91 | $8.61 |
| Resistance Level | $19.87 | $9.10 |
| Average True Range (ATR) | 0.91 | 0.36 |
| MACD | -0.24 | 0.02 |
| Stochastic Oscillator | 11.70 | 79.27 |
Price Performance
Historical ComparisonAbout CMDB Costamare Bulkers Holdings Limited
Costamare Bulkers Holdings Ltd is an international owner and operator of dry bulk vessels providing multinational transportation of dry bulk commodities for a broad range of customers. Its owned fleet consists of 38 vessels, with a total carrying capacity of approximately 3,017,000 dwt. The company's vessels transport a broad range of bulks across the shipping routes around the world. Iron ore, coal and grain constitute the majority of its cargoes.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.